常州(zhou)千紅(hong)(hong)生化(hua)制藥(yao)股(gu)份有(you)限(xian)(xian)公(gong)司(股(gu)票簡(jian)(jian)稱(cheng)(cheng):“千紅(hong)(hong)制藥(yao)”,股(gu)票代碼:002550)前(qian)(qian)身是成立于1979年(nian)的(de)常州(zhou)生物(wu)(wu)化(hua)學廠,2011年(nian)2月18日在深圳證券交(jiao)易所中小板掛牌上市(shi)。目(mu)前(qian)(qian)旗下有(you)江(jiang)蘇(su)眾紅(hong)(hong)生物(wu)(wu)工(gong)程創藥(yao)研(yan)究院有(you)限(xian)(xian)公(gong)司(簡(jian)(jian)稱(cheng)(cheng):江(jiang)蘇(su)眾紅(hong)(hong))、江(jiang)蘇(su)晶(jing)紅(hong)(hong)生物(wu)(wu)醫藥(yao)科(ke)(ke)技股(gu)份有(you)限(xian)(xian)公(gong)司(簡(jian)(jian)稱(cheng)(cheng):晶(jing)紅(hong)(hong)生科(ke)(ke))、湖北(bei)潤紅(hong)(hong)生物(wu)(wu)科(ke)(ke)技有(you)限(xian)(xian)公(gong)司(簡(jian)(jian)稱(cheng)(cheng):湖北(bei)潤紅(hong)(hong))、常州(zhou)英(ying)諾升(sheng)康(kang)生物(wu)(wu)醫藥(yao)科(ke)(ke)技有(you)限(xian)(xian)公(gong)司(簡(jian)(jian)稱(cheng)(cheng):英(ying)諾升(sheng)康(kang))等四家控股(gu)子公(gong)司。
公司(si)是國(guo)(guo)內生化(hua)制(zhi)藥行業多(duo)(duo)糖類(lei)和蛋白酶類(lei)藥品(pin)的生產(chan)經營(ying)企業,現有主要產(chan)品(pin)胰激(ji)肽原酶系列(lie)(lie)、肝(gan)素鈉及低(di)分(fen)子肝(gan)素系列(lie)(lie)、復方消化(hua)酶制(zhi)劑、門冬酰(xian)胺酶系列(lie)(lie),生產(chan)技術和質量(liang)(liang)水(shui)平均已達(da)到(dao)國(guo)(guo)際、國(guo)(guo)內專業水(shui)平。公司(si)主要品(pin)種的內控(kong)質量(liang)(liang)標(biao)準均被采納為(wei)國(guo)(guo)家標(biao)準,還(huan)參與國(guo)(guo)際藥品(pin)質量(liang)(liang)標(biao)準修訂(ding)。多(duo)(duo)個(ge)產(chan)品(pin)分(fen)別通過美(mei)國(guo)(guo)、歐盟、日(ri)本等(deng)國(guo)(guo)家政府組織的質量(liang)(liang)認證。
多(duo)年來,公司始終堅持科技創(chuang)新(xin)(xin),堅持自主(zhu)研(yan)發(fa)(fa)與產學研(yan)合作(zuo),建立了完善的產品研(yan)發(fa)(fa)和成(cheng)(cheng)(cheng)果轉化(hua)創(chuang)新(xin)(xin)體(ti)(ti)系:以(yi)(yi)海歸人(ren)員為主(zhu)體(ti)(ti)的創(chuang)新(xin)(xin)藥(yao)(yao)(yao)(yao)物(wu)研(yan)究院(yuan)、以(yi)(yi)適用人(ren)才為主(zhu)體(ti)(ti)的成(cheng)(cheng)(cheng)果轉化(hua)中(zhong)心、以(yi)(yi)經驗豐富人(ren)士(shi)組成(cheng)(cheng)(cheng)的生產質量技術(shu)研(yan)究管(guan)理(li)團隊組成(cheng)(cheng)(cheng)了“常州(zhou)千紅國際生物(wu)醫(yi)藥(yao)(yao)(yao)(yao)創(chuang)新(xin)(xin)藥(yao)(yao)(yao)(yao)物(wu)孵化(hua)基(ji)地”研(yan)發(fa)(fa)創(chuang)新(xin)(xin)平臺,平臺擁有(you)(you)近(jin)200名(ming)高素質人(ren)員,其中(zhong)有(you)(you)10多(duo)名(ming)生物(wu)醫(yi)藥(yao)(yao)(yao)(yao)博(bo)士(shi)和60多(duo)名(ming)碩士(shi)。2015年公司收購的小分(fen)子(zi)藥(yao)(yao)(yao)(yao)物(wu)創(chuang)新(xin)(xin)平臺英諾升康,與江蘇眾(zhong)紅擁有(you)(you)的生物(wu)醫(yi)藥(yao)(yao)(yao)(yao)大分(fen)子(zi)研(yan)發(fa)(fa)平臺形成(cheng)(cheng)(cheng)了互補與促進作(zuo)用,積(ji)極(ji)實(shi)現天然藥(yao)(yao)(yao)(yao)物(wu)向基(ji)因工程藥(yao)(yao)(yao)(yao)物(wu)的華麗轉身,為公司未(wei)來健康、持續和發(fa)(fa)展打(da)下良好(hao)的戰略基(ji)礎(chu)。